Fintel reports that on October 14, 2025, Canaccord Genuity maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with ...

Regeneron is expected to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $771.22, along ...

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals, Inc.’s (NASDAQ: REGN) Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the “Baird Chautauqua International and ...

It has been roughly five months since my previous Regeneron Pharmaceuticals (NASDAQ:REGN) article, where I discussed how Regeneron was still a “biotech juggernaut” thanks to their key brands of ...

An analyst downgrade weighed on a high-flying utility stock on Tuesday, Sept. 23, 2025, while an uptick in oil prices helped ...

Johnson & Johnson's Q3 2025 earnings beat forecasts, with strong oncology sales and raised guidance. Click for my updated ...